Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34652 ↗At a glance
Multizentrische Studie in International Journal of Cancer, 2023. Written by Thorsten Oliver Goetze and 11 co-authors. Institution: Institute for Clinical Cancer Research IKF, Frankfurt, Germany. Major MEDLINE topics: Adenocarcinoma, Stomach Neoplasms. Cited 7 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Lilly Deutschland.
Abstract (original language)
Based on results of prior trials (TAGS, REGARD, RAINBOW), the combination of ramucirumab beyond progression with TAS‐102 (trifluridine/tipiracil) seems to be promising in advanced esophagogastric adenocarcinoma (EGA). In this multicenter, non‐randomized, open‐label, investigator‐initiated pilot trial, ramucirumab‐pretreated patients with metastatic EGA received a maximum of 4 cycles of ramucirumab (8 mg/kg i.v. on day 1 and 15, Q2W) plus TAS‐102 (35 mg/m 2 p.o. bid on day 1‐5 and day 8‐12; Q2W). Primary endpoint was tolerability and toxicity, defining a positive trial if the SAE rate according to CTCAE 5.0 will increase
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute for Clinical Cancer Research IKF, Frankfurt, Germany.
- University Cancer Center Frankfurt, Krankenhaus Nordwest, Frankfurt, Germany.
- University Cancer Center Frankfurt, Goethe University, Frankfurt, Germany.
- Hämatologisch-Onkologische Praxis Eppendorf (HOPE) und Universitäres Cancer Center Hamburg (UCCH), Hamburg, Germany.
- München Klinikum rechts der Isar der TU München III. Medizinische Klinik und Poliklinik, Munich, Germany.
ORCID profiles: Maria Loose
Funding
- Lilly Deutschland
Cite
APA
Goetze, T. O., Stein, A., Lorenzen, S., Habibzada, T., Goekkurt, E., Herhaus, P., Loose, M., Sookthai, D., Brulin, T., Ihrig, K., Pauligk, C., & Al-Batran, S. E. (2023). Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.34652
Vancouver
Goetze TO, Stein A, Lorenzen S, Habibzada T, Goekkurt E, Herhaus P, et al. Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. 2023. doi:10.1002/ijc.34652
BibTeX
@article{Goetze2023,
author = {Goetze, Thorsten Oliver and Stein, Alexander and Lorenzen, Sylvie and Habibzada, Timorshah and Goekkurt, Eray and Herhaus, Peter and Loose, Maria and Sookthai, Disorn and Brulin, Tanita and Ihrig, Kristina and Pauligk, Claudia and Al-Batran, Salah-Eddin},
title = {Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34652}
}
EUVIMED